Related references
Note: Only part of the references are listed.The year in cardiology 2018: prevention
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2019)
Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes
Petra El Khoury et al.
DIABETES OBESITY & METABOLISM (2018)
Lipid Lowering Therapy and Circulating PCSK9 Concentration
Tsuyoshi Nozue
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2017)
Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
Ivan Pecin et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2017)
Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis
Charalambos Vlachopoulos et al.
ATHEROSCLEROSIS (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Alberico L. Catapano et al.
EUROPEAN HEART JOURNAL (2016)
PCSK9 inhibitors - past, present and future
Zeljko Reiner
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Statins in the primary prevention of cardiovascular disease
Zeljko Reiner
NATURE REVIEWS CARDIOLOGY (2013)
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
Greg Welder et al.
JOURNAL OF LIPID RESEARCH (2010)
Share Paper
